Annotating MYC status with 89Zr-transferrin imaging

Nature Medicine

Volumn 18, Issue 10, 2012, Pages 1586-1591

  Holland, Jason P ^a,c   Evans, Michael J ^a   Rice, Samuel L ^a   Wongvipat, John ^a   Sawyers, Charles L ^a,b   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD71 ANTIGEN; DEFEROXAMINE; MYC PROTEIN; TRANSFERRIN; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER MODEL; CONTROLLED STUDY; HUMAN; MALE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; DEFEROXAMINE; MALE; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, TRANSFERRIN; TRANSFERRIN; TRANSPLANTATION, HETEROLOGOUS; ZIRCONIUM;

EID: 84870289201     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2935     Document Type: Article

References (40)

1. Gatter, K.C., Brown, G., Trowbridge, I.S., Woolston, R.E. & Mason, D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539-545 (1983).
2. Neckers, L.M. & Trepel, J.B. Transferrin receptor expression and the control of cell growth. Cancer Invest. 4, 461-470 (1986).
3. Richardson, D.R. Therapeutic potential of iron chelators in cancer therapy. Adv. Exp. Med. Biol. 509, 231-249 (2002).
4. Taetle, R., Honeysett, J.M. & Trowbridge, I. Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int. J. Cancer 32, 343-349 (1983).
5. Weiner, R.E. The mechanism of 67Ga localization in malignant disease. Nucl. Med. Biol. 23, 745-751 (1996).
6. Högemann-Savellano, D. et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5, 495-506 (2003).
7. O'Donnell, K.A. et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell. Biol. 26, 2373-2386 (2006).
8. Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 (2003).
9. Tacchini, L., Bianchi, L., Bernelli-Zazzera, A. & Cairo, G. Transferrin receptor induction by hypoxia. J. Biol. Chem. 274, 24142-24146 (1999).
10. Galvez, T. et al. siRNA screen of the human signaling proteome identifes the PtdIns(3, 4, 5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake. Genome Biol. 8, R142 (2007).
11. Larson, S.M. Mechanisms of localization of gallium-67 in tumors. Semin. Nucl. Med. 8, 193-203 (1978).
12. 97Ru-transferrin uptake in tumor and abscess. Eur. J. Nucl. Med. 8, 491-494 (1983).
13. Vavere, A.L. & Welch, M.J. Preparation, biodistribution, and small animal PET of 45Ti-transferrin. J. Nucl. Med. 46, 683-690 (2005).
14. Lee, S.-I. et al. Molecular scintigraphic imaging using 99mTc-transferrin is useful for early detection of synovial infammation of collagen-induced arthritis mouse. Rheumatol. Int. 29, 153-157 (2008).
15. 131I radiolabeled transferrin in the athymic nude mouse: localization of a human colon adenocarcinoma HT-29 xenograft. Int. J. Rad. Appl. Instrum. B 17, 209-216 (1990).
16. 18F]holo-transferrin: permeability and receptor dependence. J. Nucl. Med. 40, 1547-1555 (1999).
17. Holland, J.P., Sheh, Y. & Lewis, J.S. Standardized methods for the production of high specifc-activity zirconium-89. Nucl. Med. Biol. 36, 729-739 (2009).
18. Holland, J.P., Williamson, M.J. & Lewis, J.S. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging 9, 1-20 (2010).
19. 89Zr-DFO-J591 for immunoPET of prostate-specifc membrane antigen expression in vivo. J. Nucl. Med. 51, 1293-1300 (2010).
20. Holland, J.P. & Lewis Jason, S. Zirconium-89 chemistry in the design of novel radiotracers for immuno-PET. in Technetium and Other Radiometals in Chemistry and Medicine (eds. Mazzi, U., Eckelman, W.C. & Volkert, W.A.) 187-192 (Servizi Grafci Editoriali snc, Padova, Italy, 2010).
21. Meijs, W.E., Herscheid, J.D.M., Haisma, H.J. & Pinedo, H.M. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int. J. Rad. Appl. Instrum. A 43, 1443-1447 (1992).
22. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44, 1271-1281 (2003).
23. Daniels, T.R., Delgado, T., Rodriguez, J.A., Helguera, G. & Penichet, M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144-158 (2006).
24. Haynes, B.F. et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J. Immunol. 126, 1409-1414 (1981).
25. Gotthardt, M., Bleeker-Rovers, C.P., Boerman, O.C. & Oyen, W.J.G. Imaging of infammation by PET, conventional scintigraphy, and other imaging techniques. J. Nucl. Med. 51, 1937-1949 (2010).
26. Ohkubo, Y., Kohno, H., Suzuki, T. & Kubodera, A. Relation between 67Ga uptake and the stage of infammation induced by turpentine oil in rats. Radioisotopes 34, 7-10 (1985).
27. 89Zr-albumin as a model system. J. Nucl. Med. 52, 623-633 (2011).
28. Watson, P.A. et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65, 11565-11571 (2005).
29. Aloj, L., Carson, R.E., Lang, L., Herscovitch, P. & Eckelman, W.C. Measurement of transferrin receptor kinetics in the baboon liver using dynamic positron emission tomography imaging and [18F]holo-transferrin. Hepatology 25, 986-990 (1997).
30. Aloj, L., Lang, L., Jagoda, E., Neumann, R.D. & Eckelman, W.C. Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fuorine-18](fuoromethyl) benzoate. J. Nucl. Med. 37, 1408-1412 (1996).
31. Balkwill, F. & Mantovani, A. Infammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
32. 18F-FDG. J. Nucl. Med. 46, 1522-1530 (2005).
33. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
34. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
35. Zuber, J. et al. RNAi screen identifes Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
36. Abe, N., Inoue, T., Galvez, T., Klein, L. & Meyer, T. Dissecting the role of PtdIns(4, 5)P2 in endocytosis and recycling of the transferrin receptor. J. Cell Sci. 121, 1488-1494 (2008).
37. Kim, S. et al. Regulation of transferrin recycling kinetics by PtdIns[4, 5]P2 availability. FASEB J. 20, 2399-2401 (2006).
38. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45, 17-21 (2004).
39. 89Zr-DFO- trastuzumab. PLoS ONE 5, e8859 (2010).
40. Beattie, B.J. et al. Multimodality registration without a dedicated multimodality scanner. Mol. Imaging 6, 108-120 (2007).